Chosa Oncology (CHOSA) investor relations material

Presentation of new clinical data

• Presented positive data on Platin-DRP predicting overall survival in advanced non-small cell lung cancer at the European Lung Cancer Congress.

• Platin-DRP is the first platform to predict response to platinum chemotherapy, addressing a major inefficiency in cancer treatment.

• Study showed patients with high DRP scores had a median overall survival of 16.9 months versus 5.5 months for low scores.

• Results are statistically significant and suggest a major improvement over current unguided platinum therapy.

• The DRP test uses a 205-gene profile and is protected by a patent until 2038.

Commercialization and market strategy

• Main users are oncologists for treatment planning and pharma companies for drug development.

• Revenue model includes out-licensing to diagnostic companies and pharma, with royalties or case-by-case deals.

• Target markets are balanced between the US, Europe, and China, with commercial upside per patient highest in the US.

• Potential to address 10% of the 1 million annual lung cancer patients treated with platinum, with a $1,000 test and 20% margin.

• Exploring partnerships with both global pharma and regional diagnostic companies, with flexibility for trade sale or licensing.

Operational and financial outlook

• Annual burn rate is around SEK 7 million, with potential to increase as opportunities expand.

• Liquidity is managed carefully, and capital needs may rise with accelerated development.

• Considering EU grants and other funding sources, though being listed can be a challenge for some grants.

• Increasing investor visibility through webinars, roadshows, and direct communication with potential partners.